Literature DB >> 19286368

Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS).

Alessandro Gronchi1, Ian Judson2, Toshirou Nishida3, Andres Poveda4, Javier Martin5, Peter Reichardt6, Paolo G Casali7, Axel Le Cesne8, Peter Hohenberger9, Jean-Yves Blay10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19286368     DOI： 10.1016/j.ejca.2009.02.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  9 in total

Review 1.  Advances in adjuvant therapy of gastrointestinal stromal tumors.

Authors:  K Adekola; M Agulnik
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

2.  A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.

Authors:  P A Cassier; F Ducimetière; A Lurkin; D Ranchère-Vince; J-Y Scoazec; P-P Bringuier; A-V Decouvelaere; P Méeus; D Cellier; J-Y Blay; I Ray-Coquard
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

Review 3.  Gastrointestinal stromal tumor: a bridge between bench and bedside.

Authors:  Toshirou Nishida; Tsuyoshi Takahashi; Yasuaki Miyazaki
Journal:  Gastric Cancer       Date:  2010-01-05       Impact factor: 7.370

Review 4.  Gastrointestinal stromal tumors.

Authors:  Alexander W Beham; Inga-Marie Schaefer; Philipp Schüler; Silke Cameron; B Michael Ghadimi
Journal:  Int J Colorectal Dis       Date:  2011-11-29       Impact factor: 2.571

Review 5.  Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.

Authors:  Mark Sanford; Lesley J Scott
Journal:  Drugs       Date:  2010-10-22       Impact factor: 11.431

Review 6.  Clinical and therapeutic considerations of GIST.

Authors:  M Gheorghe; D Predescu; C Iosif; C Ardeleanu; F Băcanu; S Constantinoiu
Journal:  J Med Life       Date:  2014-06-25

7.  Prediction of Tumor Recurrence in Patients with Non-Gastric Gastrointestinal Stromal Tumors Following Resection according to the Modified National Institutes of Health Criteria.

Authors:  Seung Hyeon Jang; Ji Eun Kwon; Jee Hyun Kim; June Young Lee; Sang Gyun Kim; Joo Sung Kim; Hyun Chae Jung; Jong Pil Im
Journal:  Intest Res       Date:  2014-07-25

8.  Gastrointestinal stromal tumors: Fibrinogen levels are associated with prognosis of patients as blood-based biomarker.

Authors:  Jing Lu; Shuangjiang Chen; Xuqi Li; Guanglin Qiu; Shicai He; Haijiang Wang; Libo Zhou; Yaheng Jing; Xiangming Che; Lin Fan
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

9.  Blood-Based Biomarkers Are Associated with Disease Recurrence and Survival in Gastrointestinal Stroma Tumor Patients after Surgical Resection.

Authors:  Michael Stotz; Bernadette Liegl-Atzwanger; Florian Posch; Edvin Mrsic; Michael Thalhammer; Tatjana Stojakovic; Angelika Bezan; Martin Pichler; Armin Gerger; Joanna Szkandera
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.